Evaluation of caspase 1 and sFas serum levels in patients with systemic sclerosis: Correlation with lung dysfunction, joint and bone involvement

8Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Recent studies point out at the role of apoptosis disturbances in the development of systemic sclerosis (SSc). The aim of our study was to examine caspase 1 and sFas serum levels in scleroderma patients and correlate the obtained results with skin involvement and internal organ changes. We studied 29 patients (14 with limited and 15 with diffuse SSc). The extension of skin involvement was measured using Total Skin Score (TSS). Internal organ involvement was assessed by specialist procedures. Serum caspase 1 and sFas levels were measured by enzyme-linked immunosorbent assay. We found correlation between sFas serum level and duration of Raynaud's phenomenon and TSS; caspase 1 serum level correlated only with TSS. Correlations between caspase 1 and lung dysfunction and sFas levels with joint and bone involvement in SSc patients were also observed. The obtained results revealed that disturbances of apoptosis might play a role in SSc pathogenesls. Caspase 1 and sFas serum levels correlate with the skin involvement severity, lung dysfunction, joint and bone changes.

Author supplied keywords

Cite

CITATION STYLE

APA

Dziankowska-Bartkowiak, B., Waszczykowska, E., Zalewska, A., & Sysa-Jȩdrzejowska, A. (2003). Evaluation of caspase 1 and sFas serum levels in patients with systemic sclerosis: Correlation with lung dysfunction, joint and bone involvement. Mediators of Inflammation, 12(6), 339–343. https://doi.org/10.1080/09629350310001633379

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free